Nowadays the most important and informative way to follow-up new biotherapeutics based on antibodies and their biodistribution/metabolic routes in the living body is antibody linking. Antibodies can be followed in different ways including in vivo investigations. We believe that labeling longer biological half-life antibodies with long half-life isotopes for uniquely exact and quantitative PET (89Zr) and SPECT (177Lu, 111In) imaging can give precise, fast, accurate answers in vivo. This leads up to 80% reduction of cost and animal number, and up to 50% increase in data robustness. We are using several tracers to label antibodies and follow their metabolic ways and targeting properties.